TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Debiopharm and Announce Strategic Partnership to Drive Advancements in Cancer Drug Development Using AI Digital Cell Clones

Thursday, January 11, 2024

Debiopharm, an independent biopharmaceutical firm based in Switzerland, and (TNL), a pioneering AI Digital Cells Lab company in the USA, are thrilled to announce a collaborative partnership aimed at advancing the development of an innovative cancer drug. This strategic alliance combines the unique capabilities of TNL’s AI Digital Cells Lab platform with Debiopharm’s extensive pharmaceutical expertise, propelling cancer drug development into new realms of innovation.

Key Highlights of the Collaboration:

  1. Expanding Indications: The partnership will utilize TNL’s AI Digital Cells Lab platform to explore additional indications for one of Debiopharm's cancer drugs.
  2. Drugs’ Combination Identification: Using TNL’s AI digital knockdowns, valuable combinations with other drugs in development will be identified, enhancing the therapeutic potential of Debiopharm's cancer drug.
  3. Mechanism of Action Validation: TNL’s mechanistic digital cell clones will play a crucial role in validating the mechanism of action of Debiopharm's cancer drug, ensuring a comprehensive understanding of its efficacy.
  4. Drugs’ Comparison: TNL’s digital cell clones will provide comparative analysis, enabling Debiopharm to assess its cancer drug against other existing cancer treatments.
  5. Biomarker Discovery: The TNL partnership will focus on identifying valuable predictive biomarkers.

Bertrand Ducrey, CEO of Debiopharm, expressed eagerness regarding the impact of the collaboration, stating, “We look forward to observing the influence of our partnership with on the advancement of our oncology drug programs. Integrating AI-powered solutions, such as TNL’s AI-Enabled Digital Cells Lab platform, aligns with our goal to adopt smarter practices in R&D, broadening drug applications to more cancer types and expediting the drug development timeline.”

Khai Pham, CEO of, conveyed excitement about the partnership, saying, “We are thrilled to commence this strategic collaboration with Debiopharm, a highly esteemed and innovative Swiss pharmaceutical company. We are confident that the synergy between TNL’s unique Digital Cell Clones Lab platform and Debiopharm’s profound expertise in drug R&D will demonstrate the transformative potential of AI-enabled Digital Labs from disease-target discovery to the optimization of clinical trials. As we anticipate an exciting 2024, we believe this collaboration will lead to significant advancements in the field of drug R&D for the benefit of patients.”



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit